Response to antiretroviral therapy in occult hepatitis B and HIV co-infection in West Africa

AIDS. 2013 Jan 2;27(1):139-41. doi: 10.1097/QAD.0b013e3283589879.

Abstract

This study evaluated the outcome of first-line antiretroviral therapy among 35 Ghanaians with occult HBV/HIV co-infection, comparing them over 2 years to 120 patients with HBsAg+ HBV/HIV co-infection and 230 patients without HBV co-infection. Increases in CD4 cell count and BMI were similar, whereas elevations of hepatic transaminases were more frequent in both the occult HBV and HBsAg+ patients. Occult HBV/HIV co-infection appears not to impact adversely on response to antiretroviral therapy in Ghana.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Anti-HIV Agents / therapeutic use*
  • Body Mass Index
  • CD4 Lymphocyte Count
  • Coinfection
  • Disease Progression
  • Female
  • Ghana / epidemiology
  • HIV Infections / drug therapy*
  • HIV Infections / epidemiology
  • HIV Infections / immunology
  • Hepatitis B / drug therapy*
  • Hepatitis B / epidemiology
  • Hepatitis B / immunology
  • Hepatitis B Surface Antigens / blood
  • Humans
  • Lamivudine / therapeutic use*
  • Male
  • Prevalence
  • Reverse Transcriptase Inhibitors / therapeutic use*
  • Treatment Outcome
  • Viral Load / drug effects

Substances

  • Anti-HIV Agents
  • Hepatitis B Surface Antigens
  • Reverse Transcriptase Inhibitors
  • Lamivudine